• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Adgero touts data for photodynamic drug-device combo

April 11, 2017 By Sarah Faulkner

Adgero touts data for photodynamic drug-device comboAdgero Biopharmaceuticals touted positive clinical data from studies of its late-stage photodynamic therapy platform for the treatment of cutaneous oncology indications, including unresectable metastatic breast cancer.

The Princeton, N.J.-based company’s REM-001 therapy consists of a laser light source, a light delivery device and a photosensitizer drug.

The therapy has been evaluated in 4 Phase II/III clinical trials in patients with cutaneous metastatic breast cancer, targeting patients who have previously failed radiation therapy. Adgero said it is also analyzing data from a Phase IIa trial of its therapy as a treatment for recurrent basal cell carcinoma in patients with basal cell Nevus syndrome.

REM-001 has been studied in 4 Phase 2/3 clinical trials in cutaneous metastatic breast cancer (“CMBC”) patients, primarily targeting patients who had previously failed radiation therapy. Adgero is also currently evaluating Phase 2a data of REM-001 Therapy for the treatment of recurrent basal cell carcinoma, particularly in patients with basal cell Nevus syndrome (“BCNS”).

The data presented today at the 37th ASLMS Annual Conference was a retrospective analysis that assessed REM-001 in combination with chemotherapy in 149 patients across 4 different studies. The studies consisted of patients with and without hormone therapy and chemotherapy.

The researchers examined whether or not patients saw 50% or greater reduction in lesion size. They concluded that the overall lesion response rate was 88% for the patients that received REM-001 plus chemotherapy/hormone therapy and 81% for patients receiving REM-001 alone.

Adgero said that the overall response rate was largely driven by its REM-001 therapy and was independent of chemotherapy or homone therapy, because the difference in response rates for the 2 groups was within experimental error.

“The results from our analysis indicated that REM-001 provided a high lesion response rate in those patients that were evaluable and, more importantly that the response is believed to be independent of whether or not the patient received chemotherapy. Our conclusion from this data is that REM-001 therapy may be a complementary treatment to chemotherapy for metastatic breast cancer patients that have CMBC and we believe that REM-001 Therapy holds promise as a locoregional CMBC treatment to prevent widespread lesion development,” clinical investigator Dr. Ron Allison said in prepared remarks.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Wall Street Beat Tagged With: Adgero Biopharmaceuticals

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS